Thiogenesis Therapeutics, Corp. (TSXV:TTI)

Canada flag Canada · Delayed Price · Currency is CAD
0.7500
+0.0400 (5.63%)
May 28, 2025, 9:30 AM EDT
7.14%
Market Cap 32.77M
Revenue (ttm) n/a
Net Income (ttm) -3.85M
Shares Out 45.51M
EPS (ttm) -0.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 40,630
Open 0.7100
Previous Close 0.7100
Day's Range 0.7100 - 0.7500
52-Week Range 0.5100 - 0.8000
Beta 0.79
RSI 57.31
Earnings Date May 30, 2025

About Thiogenesis Therapeutics

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Patrice Rioux
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol TTI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.